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Purpose: To evaluate different strategies for proton lung treatment planning based on four-dimensional CT
(4DCT) scans.
Methods and Materials: Twelve cases, involving only gross tumor volumes (GTV), were evaluated. Single image
sets of (1) maximum intensity projection (MIP3) of end inhale (EI), middle exhale (ME) and end exhale (EE) images;
(2) average intensity projection (AVG) of all phase images; and (3) EE images from 4DCT scans were selected as
primary images for proton treatment planning. Internal target volumes (ITVs) outlined by a clinician were imported
into MIP3, AVG, and EE images as planning targets. Initially, treatment uncertainties were not included in planning.
Each plan was imported into phase images of 4DCT scans. Relative volumes of GTVs covered by 95% of prescribed
dose and mean ipsilateral lung dose of a phase image obtained by averaging the dose in inspiration and expiration
phases were used to evaluate the quality of a plan for a particular case. For comparing different planning strategies,
the mean of the averaged relative volumes of GTVs covered by 95% of prescribed dose and its standard deviation
for each planning strategy for all cases were used. Then, treatment uncertainties were included in planning.
Each plan was recalculated in phase images of 4DCT scans. Same strategies were used for plan evaluation except
dose-volume histograms of the planning target volumes (PTVs) instead of GTVs were used and the mean and
standard deviation of the relative volumes of PTVs covered by 95% of prescribed dose and the ipsilateral lung dose
were used to compare different planning strategies.
Results: MIP3 plans without treatment uncertainties yielded 96.7% of the mean relative GTV covered by 95% of
prescribed dose (standard deviations of 5.7% for all cases). With treatment uncertainties, MIP3 plans yielded 99.5%
of mean relative PTV covered by 95% of prescribed dose (standard deviations of 0.7%). Inclusion of treatment
uncertainties improved PTV dose coverage but also increased the ipsilateral mean lung dose in general, and
reduced the variations of the PTV dose coverage among different cases. Plans based on conventional axial CT scan
(CVCT) gave the poorest PTV dose coverage (about 96% of mean relative PTV covered by 95% isodose) compared
to MIP3 and EE plans, which resulted in 100% of PTV covered by 95% isodose for tumors with relatively large
motion. AVG plans demonstrated PTV dose coverage of 89.8% and 94.4% for cases with small tumors. MIP3 plans
demonstrated superior tumor coverage and were least sensitive to tumor size and tumor location.
Conclusion: MIP3 plans based on 4DCT scans were the best planning strategy for proton lung treatment planning.
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Proton treatment for lung cancer can spare or mini-
mize dose to contralateral lung tissue. We have been
treating medically inoperable non-small-cell lung carci-
noma (NSCLC) for more than ten years [1-3]. We have
used three regimens: (a) X-rays followed by proton
boost, with a conventional fraction rate of 1.8 Gy per
day; (b) protons only, with a fraction rate of 1.8/2.0 Gy
per day; (c) hypofractionated protons, with a fraction
rate of 6/7 Gy per day in 10 fractions. Patients were
assigned to one of the protocols based on their medical
condition and tumor grade. Bush et al. [1] followed up
37 patients with early-stage NSCLC and reported better
survival and local control using proton therapy with an
updated review published in 2010 [2]. Moyers et al. [4]
studied the methodologies and tools for proton lung
treatment planning, and pointed out that a proton beam
design should include tumor motion and setup uncer-
tainties instead of creating new targets. That study intro-
duced aperture and compensator design using margins
and smearing to take into account tumor motion and
setup uncertainties. The smearing method was similar to
the compensator design proposed by Urie et al. [5] to
account for setup uncertainties and tumor motion.
We have used conventional axial CT (CVCT) images for
proton lung treatment planning before four-dimensional
CT (4DCT) became available. Severe motion artifacts can
be introduced during acquisition of CVCT images for a
moving target [6-8]. Such artifacts distort the volume of
structures when substantial motion occurs. The artifacts,
in turn, adversely affect proton lung treatment planning.
4DCT synchronizes the time-resolved CT data acquisi-
tion with respiratory motion monitored by a real-time po-
sition management (RPM) system. In the cine mode of
4DCT scanning, the CT table keeps the same position in
a breathing cycle of a patient. Multiple images are re-
constructed for each table position. Images of the same
breathing phase at different CT table positions are sorted
together into different phase images. A breathing cycle can
be divided into different phases (0%, 30%, 50%, 70% and
90%), which represent the end-inhale (EI), middle-exhale
(ME), end-exhale (EE), middle-inhale (MI), and near-
end-inhale (NEI) phases of a breathing cycle. Each phase
corresponds to a near static moment in the breathing cycle
of a patient. The corresponding images of each phase con-
tain fewer motion artifacts.
Engelsman et al. [9] have proposed a proton lung treat-
ment planning strategy based on 4DCT scanning. It com-
bines three plans using EI, ME and EE images into a
single treatment plan. This technique requires special
tools in the treatment planning system to combine mul-
tiple plans from different phase images. Although it gives
acceptable results, it is not clinically efficient. Kang et al.
[10] compared four planning strategies based on imagesof: (1) AVG, (2) free breathing helical CT, (3) MIP, and (4)
AVG with the density correction of a moving tumor
(AVG_RIGTV). They suggested that the AVG_RIGTV ap-
proach be employed for proton lung treatment planning.
This approach requires a uniform density substitution
of 100 HU (water = 0 HU) for the entire IGTV. This ap-
proach ensures coverage of the tumor but delivers a
higher dose to the surrounding tissue. Moreover, uniform
density substitution will have different effect on treatment
planning outcome for different tumor sizes and locations.
Our clinical outcomes and experiences of proton lung
treatment were based on CVCT plans. Herein we com-
pare proton lung treatment planning using 4DCT scans
against plans derived from this benchmark. MIP3, AVG
and EE images from 4DCT scans were selected as the
primary images for planning. ITVs outlined by a clin-
ician were exported from the original treatment plans
and imported into MIP3, AVG, and EE images as the
planning targets. Initially there were no uncertainties in-
cluded in the planning process. This was done to com-
pare different planning strategies without institution
specific preferences for treatment planning uncertainties.
Later, CT number, treatment setup, and proton beam
range uncertainties were included in the plans. The plans
were imported and recalculated in phase images of 4DCT
scans for plan evaluation and comparison of different
planning strategies. We will show that MIP3 planning
strategy, introduced here, gives the best overall tumor
coverage, and surrounding tissue sparing, irrespective of
the magnitude of tumor motion, tumor size or location.Material and methods
CVCT plan
The treatment planning system employed at our institu-
tion (Odyssey 4.8; Optivus Proton Therapy), automatic-
ally selects proton beam energy and modulation, calculates
proton beam range shift, and generates an aperture and
compensator for each portal to cover a target laterally and
distally. The aperture is shaped by the target with a margin
for proton beam penumbra and treatment setup uncer-
tainty. The compensator is designed by the straight-line
ray tracings of water-equivalent depths in the target. The
thickness of a compensator at each ray line is the difference
between the radiological path length of the 90% distal dose
fall-off of a proton beam and the water equivalent depth of
a target at the distal end. The smearing in the compensator
design compares the thickness of the compensator at a ray
line with its surrounding ray lines in a radius and chooses
the smallest value as the thickness of the compensator
at the ray line. This radius, called the smearing radius, is
determined by tumor motion, proton beam range, and
treatment setup uncertainty. The smeared compensator
increases the penetration of the proton beam and ensures
Figure 1 A typical proton treatment set up. Patient is in the
whole body pod. Blue wax compensator and digital image receptor
are visible in the figure.
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tion and treatment setup uncertainties.
A patient is immobilized supine in a whole-body pod
for CT scanning and subsequent proton lung treatment
(Figure 1). The 4DCT scan is performed by a GE 64-slice
LightSpeed QX/I CT scanner in the cine mode. A Varian
RPM system records the respiratory motion. The 4DCT
scan and respiratory profile are temporally correlated. EI,
ME, EE, MI, and NEI images are retrospectively sorted
according to respiratory phases. CVCT images are ac-
quired by conventional axial CT scan in free-breathing
mode. Twelve patients, who received proton lung treat-
ments for NSCLC at our institution with different tumor
sizes and locations, were selected for the study. The cases,Table 1 Tumor location, inspiration and expiration durations,
and EE phases, and in 3D





in EE phase (c
A Right upper lobe 1.6 0.5 0.4
B Right upper lobe 1.7 2.4 1.3
C Left upper lobe 1.5 1.5 2
D Right upper/middle lobe 2 1.8 6.5
E Right upper lobe 1.2 3.3 7.4
F Right middle lobe 1.5 2.5 7.7
G Left upper lobe 3.7 5.3 8.1
H Left lower lobe 1.4 1.5 17.9
I Left lower lobe 1.5 2.4 20.0
J Left upper/lower lobe 2.3 2.3 25.7
K Right upper lobe 1.7 2.1 69.8
L Left upper/lower lobe 0.7 0.5 95.4named A-L, were treated with either 60 Gy in 30 fractions
or 60/70 Gy in 10 fractions. Proton lung treatments were
planned using CVCT images. MIP images as alternate
studies were correlated with CVCT images to outline
ITVs as planning targets by a clinician. Treatment setup,
proton beam range, and CT number uncertainties were
included in the plans. Apertures were shaped by ITVs with
margins for proton beam penumbra and treatment setup
uncertainty. Compensators were designed to stop proton
beams at the distal edges of ITVs, allowing margins for
distal dose fall-off of proton beams. The smearing used in
the compensator design was determined by the maximum
motion of ITVs, treatment setup uncertainty, and 3%
of proton beam range for proton scattering [4]. The
smearing compensated for the density variations of ITVs
and motion artifacts in CVCT images that contained the
randomized superimposed moving targets.
All cases contained only one target, except case J, which
had two lesions nested in the upper and middle lobes of
the left lung. Table 1 indicates the locations of all the tu-
mors, their motion characteristics, and the tumor size in
the EE phase. The tumor of case L was nested along the
anterior side of the lung and adjacent to the chest wall
and heart. In the remaining cases, tumors were located
along the posterior or middle side of lung. In terms of
breathing patterns, L and G represented extreme cases
with breathing periods of 1.2 and 9.0 seconds, respectively.
The remaining cases had breathing periods of about 3 to
5 seconds. For most cases expiration was longer or equal
to inspiration; cases A, D, and L being notable exceptions.
Patients generally stay near EE phase longer. Tumor vol-
umes in the EE phase varied from 0.4 to 95.4 cubic centi-
meters (cc), as listed in Table 1. Tumor motion in three
dimensions (3D) was calculated by r.m.s of motions in thetumor volumes in EE phase, tumor motion between EI
c)
Motion (mm) between EI and EE phases Tumor motion
in 3D (mm)Left-right Superior-inferior Anterior-posterior
1.5 3.2 1.3 2.2
3 3 2 2.7
1.1 6.3 4.0 4.4
1.5 8 5.5 5.7
1.6 3.4 1.2 2.3
7.2 31.0 8.6 19.0
2.0 13 12 10.3
1.3 24.4 5.5 14.5
0.6 15.7 0.5 9.1
2.1 10.7 6.3 7.3
4.3 5.1 7.4 5.8







Figure 2 Tumor positions and lung volumes in EI, ME and EE
images for cases F, G, H and I. The double lines correspond to the
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tions. Cases A, B, and E had similar tumor motions in 3D,
i.e., of about 3 mm; these motions were less than the rest
of cases except case L, which had the largest tumor vol-
ume and minimum tumor motion in 3D. Case F had the
maximum tumor motion of 31 mm along the superior-
inferior direction. Case K had the largest tumor motion
in the anterior-posterior direction of 7.4 mm. Comparing
tumor volumes in EE images, cases A through C had
small tumor volumes of less than 2 cc; cases D through G
had tumor volumes of 7 to 8 cc; cases H through J had
tumor volumes of 18 to 26 cc; and cases K and L had
tumor volumes of 70 and 95 cc.Figure 3 Tumor positions and lung volumes in EI, ME and EE
images of case D, J and K, the double lines correspond to the
tumor positions in ME images.Primary Images and ITVs for proton treatment planning
MIP images have artificially higher tissue densities and
thus were not selected as primary images for proton
planning. Instead, the MIP images from EI, ME, and EE
phases, named as MIP3 images, and introduced in this
study, were used as primary images for treatment planning.
MIP3 and MIP images are based on the same principle ofimage reconstruction, but MIP3 images contain the magni-
tude of tumor motion but do not artificially increase the
tissue densities as seen in MIP images. Lung tissue gener-
ally contains its maximum air volume in the EI phase and
its minimum air volume in the EE phase. Tumors, thus,
might show greater movement from the EI to ME phase
than from the ME to EE phase because of the faster out-
ward movement of air volume immediately after the EI
phase. Figure 2 displays the comparison of lung volumes
for different tumor positions relative to their anatomy in
EI, ME, and EE phases for case F, G, H, and I. There were
relatively larger tumor motions from the EI to ME than
from the ME to EE phases, which indicated that tumors
with large motion stayed near the EE phase longer. For 3D
tumor motion of less than 8 mm, as in cases D, J, and K,
shown in Figure 3, there was relatively less tumor move-
ment from the EI to EE phase. Accordingly, EE images
were chosen as primary images from 4DCT scanning for
proton lung treatment planning comparisons. Previous
studies [10] demonstrated that AVG images with density
correction of moving targets were better for proton lung
treatment planning. We selected (1) MIP3, (2) AVG, and
(3) EE images as the primary images from 4DCT scans for
this planning study. ITVs from CVCT plans were imported
into MIP3, AVG, and EE images as planning targets. The
corresponding plans for MIP3, AVG, and EE were com-
pared with CVCT plans for quality evaluation of a plan-
ning strategy.
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The cases were planned with posterior-anterior and left-
right lateral beams, except case H, which used posterior-
anterior and left-anterior-oblique beams. Treatment setup,
CT number, and proton beam range uncertainties were
excluded from the plans in order to compare different
planning strategies independent of all institution specific
uncertainties. The aperture of each portal was shaped by
ITVs with a margin equal to the proton beam’s 95% to
50% penumbra for lateral dose fall-off. The compensator
of each portal was designed to have 95% distal dose cover-
age of the ITVs. ITVs from EE images had the outline of
moving targets and contained tumor densities in the EE
phase only. ITVs from AVG images contained superim-
posed moving tumors with averaged tissue densities lower
than solid tumors in the EE phase. ITVs from EE and
AVG images required density corrections for the compen-
sator design in the EE and AVG plans. The density of a
solid tumor in the EE phase was used to replace densities
of ITVs in EE and AVG images to ascertain adequate beam
penetration. ITVs from MIP3 images were the superim-
posed tumors from EI, ME, and EE phases, which con-
tained tumors at the middle and two extreme phases of a
breathing cycle. The density variations of tumors in be-
tween other phases had to be compensated for ITVs as
planning targets in the MIP3 plans. The smearing tech-
nique was applied in the compensator design of MIP3








0:03Rangeð Þ2þ 1 2MaxMotionCVCT ;MIP
 2r
Where SRMIP3 and SRCVCT were the smearing radii
used for MIP3 and CVCT plans, MaxMotion EI, ME and
MaxMotion CVCT, MIP were the maximum tumor motion
perpendicular to a beam direction between EI and ME,
and CVCT and MIP images, and Range represented the
proton beam range. In the equations above, 3% of pro-
ton beam range accounted for proton beam scattering
along its path; the second part compensated for tumor
motion in the compensator design of MIP3 and CVCT
plans. The smearing radius of MIP3 plans was calculated
from the maximum tumor motion in between the EI
and ME phase. This was done because lung tumors gen-
erally have greater movement from EI to ME phases
than from ME to EE phases. The smearing radius be-
tween the EI to ME phase will not only compensate for
tumor movements between the EI to ME phase, but also
between the ME to EE phase.
CVCT images contain randomly superimposed mov-
ing tumors during image acquisition by axial CT scan.The smearing radius of CVCT plans used the maximum
tumor motion between CVCT and MIP images to com-
pensate for tumor movements not captured by CVCT
images. The smearing radius of a MIP3 plan was domi-
nated mainly by the large tumor motion along the
superior-inferior direction between the EI and ME phases.
The smearing radii of CVCT plans of cases F through J
were larger than those of MIP3 plans. The maximum
tumor motions between CVCT and MIP images were lar-
ger compared to tumor motion between the EI and ME
phases of cases F through J. The smearing radii of CVCT
and MIP3 plans of cases A, B, C, and E were smaller than
those of cases F through J. The small tumor motion of
cases A, B, C, and E decreased the differences of the
smearing radii between CVCT and MIP3 plans. The
smearing radii of CVCT and MIP3 plans of cases K and L
were mainly dominated by proton beam scattering along
the beam paths.
For each case, CVCT, MIP3, AVG, and EE plans were
fixed and imported into EI, ME, EE, MI, and NEI images
for the plan evaluation, in which GTVs and the ipsilat-
eral lung were outlined. The ipsilateral lung excluded
GTVs. The mean dose and dose-volume histograms of
lung were calculated. GTV dose instead of PTV dose
was used for plan evaluation because no treatment un-
certainties were included at this stage in the planning
process. The relative volumes of GTVs covered by 95%
of prescribed dose and mean lung dose from EI, ME, EE,
MI, and NEI images were averaged by the inspiration
and expiration duration of a case in a breathing cycle
as follows:
GV95 ¼ fInD V95EI þ V95MI þ V95NEIð Þ=3þ ExD
V95EE þ V95MEð Þ=2g= InDþ ExDð Þ
GMLD ¼ fInD MLDEI þMLDMI þMLDNEIð Þ=3þ ExD
MLDEE þMLDMEð Þ=2g= InDþ ExDð Þ
Where GV95 and GMLD were, respectively, the aver-
aged relative volumes of GTVs covered by 95% of pre-
scribed dose and mean lung dose from EI, ME, EE, MI,
and NEI images; InD and ExD were the inspiration and
expiration durations; V95EI, V95MI, V95NEI, V95EE, and
V95ME represented the relative volume of GTVs covered
by 95% of prescribed dose in the EI, MI, NEI, EE, and
ME phases; and MLDEI, MLDMI, MLDNEI, MLDEE, and
MLDME were the mean lung doses in the EI, MI, NEI,
EE, and ME phases. GV95 and GMLD displayed the aver-
age tumor volume covered by 95% of the prescribed dose
and mean lung dose in a breathing cycle. In addition, we
calculated the mean averaged relative volumes of GTVs
covered by 95% of prescribed dose for all cases in the
study (MGV95) to display the overall tumor dose coverage
Wang et al. Radiation Oncology 2013, 8:73 Page 6 of 10
http://www.ro-journal.com/content/8/1/73for a planning strategy. The standard deviation (STDGV95)
of a planning strategy from MGV95 was calculated as well.
Treatment planning including uncertainties
In this case, treatment planning uncertainties, viz., treat-
ment setup, CT number, and proton beam range uncer-
tainties were included in CVCT, MIP3, AVG, and EE
plans. The treatment setup uncertainty for proton lung
treatment using a whole-body pod is about 5 mm, which
increased the lateral margins between aperture and ITVs,
and increased the smearing of compensators. A smearing
radius of 5 mm was used in the compensator design of
AVG and EE plans for compensating the setup uncertainty
in the plans. To account for the setup uncertainty, the
smearing radii for CVCT and MIP3 plans were increased
by 5 mm in addition to the already calculated SRCVCT and
SRMIP3. The distal margin of ITV for the compensator de-
sign was calculated as
0.035 × ITV distal depth(water equivalent) + 3 mm,
where first part represents CT number uncertainty and
the second part represents proton beam range uncer-
tainty. The plans were imported into and recalculated in
EI, MI, NEI, EE, and ME phase images, in which PTVs
were derived from GTVs with the margin equal to treat-
ment setup uncertainty in the direction perpendicular
to proton beam direction. From each of CVCT, MIP3,
AVG, and EE plans, dose volume histograms of PTVs
and those of ipsilateral lung in EI, ME, EE, MI, and NEI
phases were calculated by averaging over the inspiration
and expiration duration in a breathing cycle as discussed
above. The averaged relative volumes of PTVs covered
by 95% of prescribed dose (PV95), mean lung dose
(PMLD), and relative volumes of ipsilateral lung receiving
more than 20 Gy (LV20) from CVCT, MIP3, AVG, and
EE plans were compared. The mean PV95 of all the cases
(MPV95) and standard deviation (STDPV95) of PV95 were
calculated for each CVCT, MIP3, AVG, and EE planning
strategy for all cases. These calculations were carried out
to demonstrate the overall PTV dose coverage and sen-
sitivity of a particular planning strategy to different
tumor sizes and locations in the presence of treatmentTable 2 Averaged relative volumes of GTVs covered by 95% of
Case A B C D E F
GV95 (%) CVCT plan 64.9 84.1 97.5 99.8 97.3 95.1
MIP3 plan 82.2 88.3 97.1 100 96.9 100
AVG plan 64.0 86.3 90.9 96.3 95.3 99.8
EE plan 69.1 89.7 96.3 99.8 96.5 99.9
GMLD (Gy) CVCT plan 1.0 1.9 3.6 2.9 3.6 4.9
MIP3 plan 1.1 2.0 3.7 3.0 3.8 5.1
AVG plan 0.9 2.0 2.9 2.5 3.4 4.1
EE plan 0.8 2.0 3.1 2.5 3.4 4.2
Mean ipsilateral lung dose (GMLD) (Gy) from CVCT, MIP3, AVG and EE plans (treatmeuncertainties which are included in the planning process.
The optimal planning strategy was selected based on
this analysis.
To further evaluate the robustness of our technique we
planned two cases, case A, smallest tumor, and case F, lar-
gest motion, under over-irradiate and under-irradiate
modes. Under the over-irradiate mode the beam is allowed
to penetrate deeper by 0.035 x ITV depth (water equiva-
lent depth) + 3 mm, and for the under-irradiate mode the
beam is retracted by the same amount. It is in addition
to the uncertainties already included in planning for the
PTV. This was done to create extreme situations and see
how MIP3 compares with other strategies under these
conditions.
Results
Table 2 lists the average relative volumes of GTVs re-
ceiving 95% of prescribed dose, and the average mean
ipsilateral lung dose in EI, MI, NEI, EE, and ME phases
from CVCT, MIP3, AVG, and EE plans in the absence of
uncertainties. Cases A and B had less than 95% of the
average relative volumes covered by 95% of prescription
dose for all plans. MIP3 planning showed the best over-
all coverage by the 95% isodose covering more than 95%
of GTV for all cases from C to L, resulting in the best
MGV95 of 96.7% and lowest standard deviation (5.7%).
AVG plans performed worst, with the lowest MGV95
of 93.6% and highest standard deviation (10.4%). These
results suggested that the MIP3 plan yielded superior
tumor coverage irrespective of tumor size and location.
On the other hand, all planning strategies delivered simi-
lar lung dose (GMLD) for every case studied; but dose
varied with tumor size and location. Irradiation of large
tumors (case K and L, Table 1) resulted in higher dose
to normal lung (Table 2).
Table 3 lists the average relative volumes of PTVs cov-
ered by 95% of prescribed dose (PV95) from CVCT,
MIP3, AVG, and EE plans, with treatment uncertainties
included in the planning process. The mean of the average
relative volumes of PTVs covered by 95% of prescribed
dose (MPV95) from each of the planning strategies andprescription dose (GV95) for different planning strategies
G H I J K L MGV95 STDGV95
93.8 97.0 99.9 99.8 100 98.4 94.1 10.2
96.3 100 100 99.8 99.7 100 96.7 5.7
91.5 100 100 99.7 100 100 93.6 10.4
94.4 100 100 99.8 100 99.8 95.4 8.9
6.6 4.1 5.6 7.3 11.1 11.7
6.9 4.5 5.3 7.3 11.5 11.0
5.5 4.0 4.5 6.2 11.3 11.0
5.7 3.9 4.7 6.5 11.5 11.0
nt uncertainties not included).
Table 3 Average relative volumes of PTVs covered by 95% of prescription dose (PV95), and MPV95 and STDPV95, and
average ipsilateral lung volumes receiving more than 20 Gy (LV20) and Mean lung dose (PMLD) (Gy) from CVCT, MIP3,
AVG and EE plans (treatment uncertainties included)
Case A B C D E F G H I J K L MPV95 STDPV95
PV95 (%) CVCT plan 96.1 98.5 100 99.9 99.5 95.4 95.6 99.8 99.9 99.7 98.9 97.8 98.4 1.7
MIP3 plan 98.4 99.1 100 100 99.9 100 99.7 99.8 99.8 99.8 99.3 97.8 99.5 0.7
AVG plan 89.8 94.4 100 100 100 100 98.5 99.8 99.8 99.8 99.5 97.0 98.2 3.1
EE plan 96.8 99.7 100 99.9 100 100 99.6 99.9 100 99.8 99.8 97.4 99.4 1.1
LV20 (%) CVCT plan 3.9 8.0 13.6 7.6 13.7 18.7 23.8 12.1 20.0 25.7 32.3 30.3
MIP3 plan 5.1 8.4 15.1 9.3 13.7 18.6 23.0 11.5 18.2 25.9 32.8 30.8
AVG plan 2.6 7.1 13.4 7.9 13.2 19.0 20.5 11.9 19.9 25.7 33.4 31.0
EE plan 4.0 8.2 13.4 7.9 13.2 19.1 21.3 11.2 21.0 25.8 33.1 31.0
PMLD (Gy) CVCT plan 2.4 3.9 6.7 4.3 6.3 8.4 10.8 6.7 9.1 13.0 15.7 14.7
MIP3 plan 2.8 4.0 7.1 5.1 6.2 8.8 10.1 6.5 8.4 12.7 16.0 15.0
AVG plan 1.7 3.4 6.6 4.4 6.1 8.6 9.6 6.5 8.8 12.7 16.3 15.1
EE plan 2.4 3.9 6.5 4.4 6.1 8.7 9.9 6.2 9.2 12.8 16.5 15.2
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Results indicate that, in the presence of treatment uncer-
tainties, MIP3 planning methodology gave the best PTV
coverage, with better than 98% PTVs covered by 95% iso-
dose line; case L being at the lower end at 97.8% coverage.
Based on MPV95 and STDPV95 criteria, MIP3 planning
yielded superior overall results as well. Although for cer-
tain cases other methodologies also performed satisfacto-
rily, MIP3 planning demonstrated the least sensitivity to
tumor location and tumor size, resulting in optimal tumor
coverage as evidenced by the maximum PV95, MPV95 and
least STDPV95. Also listed in Table 3 are the ipsilateral
lung volumes receiving more than 20 Gy (LV20), and the
mean lung dose (PMLD) from CVCT, MIP3, AVG, and EE
plans averaged over the inspiration and expiration dur-
ation of each case. Based solely on LV20 and PMLD criteria,
no clear patterns emerged which could point toward a
superior planning strategy. But combined with superior
tumor coverage and least sensitivity to tumor size and lo-
cation; MIP3 proved to be a winning strategy. For ex-
ample, based on LV20 and PMLD criteria; AVG plan gives
best results for case A; but PV95 of only 89.8% makes this
an unacceptable planning strategy (Table 3). As an illus-
trative example, Figure 4 shows the averaged dose volume
histograms of PTVs and ipsilateral lung comparing MIP3
with other planning strategies for case A (smallest tumor)
and case F (largest tumor motion).
Table 4 lists PV95 and PMLD for cases A (smallest tumor)
and F (largest motion) using over-irradiate and under-
irradiate modes for different planning strategies. For com-
parison the results for nominal irradiation (as described
earlier) are also listed. As can be seen from the results in
Table 4, even under these extreme situations (highly un-
likely but not improbable), MIP3 planning strategy fares as
well as or better than other strategies. Also, as can be seenfrom the results in Table 4, under-shooting is more serious
a problem in proton therapy than over-shooting. Since a
proton beam stops abruptly near the end-of-range, the por-
tion of the tumor beyond the distal edge of the Bragg peak,
as happens in under-shooting, is left virtually cold, leading
to serious under-dosing, especially, for small tumors.
Discussion
Our study compared different treatment planning strat-
egies using 4DCT data to accommodate motion in pro-
ton lung treatment planning. Plans were done with and
without treatment uncertainties. As shown in Table 2,
when uncertainties are not included all plans demonstrated
similar GTV dose coverage for cases H through L. These
cases represent relatively large tumor volumes. On the
other hand, cases involving small tumor sizes (A through E)
showed large variations in GTV dose coverage. The chal-
lenge for a good planning strategy comes from its capability
of providing adequate dose coverage to small tumors in the
presence of motion. Cases A and B, with the smallest tumor
volumes (Table 1), showed the worst GTV dose coverage
regardless of planning strategy (Table 2) because small tu-
mors are more sensitive to movements and deformation.
AVG plans yielded inferior GTV dose coverage for cases
C through E compared to MIP3, EE, and CVCT plans. This
result, and the results of cases A and B, indicate that an
AVG plan strategy needs higher density corrections of the
ITVs for small tumors to compensate lower tissue densities
along proton beam paths of AVG images. As can be seen in
Table 2, MIP3 plans, overall, resulted in the best GTV dose
coverage (GV95) and the highest mean GTV dose (MGV95)
with the minimum standard deviation (STDGV95) for all
cases studied.
Inclusion of treatment uncertainties increased the lateral
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Figure 4 Comparison of MIP3 planning strategy with other planning strategies for the case of a tumor with smallest size (case A):
(a) – (c); and for the case of a tumor with maximum motion (case F): (d) – (f).
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Table 4 Average relative volumes of PTVs covered by 95% of prescription dose (PV95), and Mean lung dose (PMLD) (Gy)
from CVCT, MIP3, AVG and EE plans under conditions of nominal, over irradiation and under irradiation
Case A F
Irradiate mode Over Under Nominal Over Under Nominal
PV95 (%) CVCT plan 95.6 77.4 96.1 100 91.0 95.4
MIP3 plan 96.9 96.0 98.4 100 98.4 100
AVG plan 95.7 73.7 89.8 100 99.7 100
EE plan 95.7 76.3 96.8 100 99.9 100
PMLD (Gy) CVCT plan 2.9 1.6 2.4 8.7 6.3 8.4
MIP3 plan 3.0 1.7 2.8 9.0 7.0 8.8
AVG plan 2.9 1.6 1.7 9.0 7.3 8.6
EE plan 2.9 1.7 2.4 9.1 7.4 8.7
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creased smearing in the compensator design. The in-
creased margins improved the PTV dose coverage, but
they also increased dose to the ipsilateral lung compared
to the plans without treatment uncertainties (Tables 3). As
shown in Table 3, the PTV dose coverage of cases C
through E was improved compared to the GTV dose cov-
erage from the plans without treatment uncertainties. For
large tumors (cases H through L), dose coverage with and
without uncertainties was very similar (within 2%). On the
other hand, cases involving small tumors (A through E)
showed large variations in GTV dose coverage. PTV dose
coverage for cases C through E and H through K from all
planning strategies produced similar results (Table 3). In-
clusion of treatment uncertainties reduced the differences
of the PTV dose coverage from different planning strat-
egies, for most cases. The most significant improvement
in dose coverage is seen in small tumors when uncertain-
ties are included; the smallest tumors (cases A and B)
showing the maximum improvement in dose coverage
(Table 2, Table 3); except with the AVG plan. AVG plans
displayed poor PTV dose coverage for small tumors, espe-
cially cases A and B. In general, MIP3 and EE plans dem-
onstrated better PTV dose coverage than CVCT and AVG
plans. EE and AVG plans had the same density corrections
for ITVs. However, EE plans yielded superior PTV dose
coverage relative to AVG plans. The result that AVG plans
need higher density corrections of ITVs agrees with the
MD Anderson study [10]. The density corrections of ITVs
in EE plans might introduce additional planning uncer-
tainties. If a treatment planning system could capture
ITVs from all breathing phases and superimpose them
into EE images, EE planning can be a good planning strat-
egy for proton lung treatment.
The mean lung dose from the plans with treatment
uncertainties increases (Table 3). Treatment uncertain-
ties have a more pronounced effect on mean lung dose
for large tumors than for small tumors. Accordingly, lar-
ger ITV margins should be considered for very smalltumors, such as for cases A and B. The CVCT plan for
case G created the worst case scenario: lowest PTV dose
coverage (PV95 =95.4%) and high lung dose (LV20 =
23.8 Gy, PMLD = 10.8 Gy). The CVCT plan for case F,
also showed poor PTV dose coverage. Both cases were
characterized by large tumor movements with different
motion patterns. The tumor in case F had the maximum
movement along the superior-inferior direction, with the
breathing period of 4 seconds. Case G had roughly the
same movements along the superior–inferior and anterior–
posterior directions, with the breathing period of 9 seconds.
Motion artifacts in CVCT images might affect their ITV
outlines, decrease the PTV dose coverage, and affect the
ipsilateral mean lung dose differently.
Engelsman et al. [9] indicate that the ideal proton
lung planning strategy using 4DCT scans is to design
multiple plans using all phase images from a breathing
cycle and combining them into one treatment plan. Ap-
ertures and compensators from the multiple plans have
to be combined to create one aperture and compensator
for each beam for treatment. The combined aperture
will be similar to the aperture shaped to ITVs. The com-
bined compensator will correspond to the maximum
proton beam range required to cover the deepest target
with the minimum range shift. The differences between
the combined compensator and the compensator designed
for ITVs in MIP3 plans may come from the variations
in patient thickness along the proton beam path from dif-
ferent phases during a 4DCT scan. These variations from
4DCT scanning are minimal for a patient immobilized in a
whole-body pod with free breathing. The treatment plan-
ning strategy of using multiple phase images or MIP3 im-
ages from 4DCT scans will be similar. However, the
workload will increase significantly for designing multiple
plans for all phase images compared to MIP3 plans from
4DCT scanning. MIP3 plans demonstrated the best PTV
dose coverage and least sensitivity to tumor sizes and
locations. Figure 4 illustrates this point for two very dif-
ferent cases: Case A (a-c) with smallest tumor size and
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egy is far superior than CVCT planning based on axial CT
scans, predating the availability of 4DCT. The 4DCT scans
are much faster (a minute or so) than axial scans
(8–10 minutes). These scans capture motion more realis-
tically, reduce motion artifacts, resulting in superior
dosimetry, and considerably reduce patient exposure to
CT radiation. MIP3 planning strategy investigated in this
study is easy to implement in the clinic for routine proton
lung treatment planning.
Conclusions
Proton lung treatment can be improved by using 4DCT
scanning to capture tumor motion correctly. In this study,
three planning strategies, using MIP3, AVG, and EE im-
ages as the primary images from 4DCT scans, were dem-
onstrably superior to CVCT planning from conventional
axial CT scans. Among the twelve cases selected for the
study, AVG plans displayed the lowest PTV dose coverage
for small tumors and were most sensitive to tumor sizes
and locations. CVCT planning demonstrated lower PTV
dose coverage compared to MIP3, AVG, and EE plans for
tumors with relatively large motion. EE plans were super-
ior to CVCT and AVG plans. Inclusion of treatment un-
certainties, in general, improved PTV dose coverage and
reduced PTV dose differences for small tumors using dif-
ferent planning strategies. Among plans with and without
treatment uncertainties, MIP3 plans demonstrated the
best overall GTV and PTV dose coverage and least sensi-
tivity to tumor sizes and locations. MIP3 planning based
on 4DCT scans, investigated in this study, proved to be a
superior planning strategy that could easily be implemented
in the clinic for routine proton lung treatment planning.
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